Cara Therapeutics, Inc.
CARA
Classifica tra le azioni
#9894
Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating... Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating primarily within the United States. Its core business involves discovering and commercializing novel drug compounds, with a particular emphasis on addressing itching (pruritus) and pain by selectively modulating kappa opioid receptors. The company's therapeutic pipeline includes potential medicines designed to interact with the body's peripheral nervous system and immune cells. KORSUVA (difelikefalin), an injectable formulation, stands as their flagship product. It is approved for treating moderate-to-severe pruritus linked to chronic kidney disease in adult patients undergoing hemodialysis. Additionally, Cara Therapeutics is advancing an oral version of KORSUVA (difelikefalin) through its pipeline. This oral candidate has successfully completed Phase II clinical trials for relieving pruritus associated with atopic dermatitis and chronic kidney disease not requiring dialysis (NDD-CKD). It is also currently undergoing Phase II evaluation for pruritus related to chronic liver disease (specifically primary biliary cholangitis) and for notalgia paresthetica. The company has established international licensing agreements: one with Maruishi Pharmaceutical Co., Ltd for the development, production, and commercialization of difelikefalin-containing products targeting acute pain and uremic pruritus in Japan, and another with Chong Kun Dang Pharmaceutical Corporation for similar activities concerning difelikefalin products in South Korea. Cara Therapeutics, Inc. was established in 2004 and is headquartered in Stamford, Connecticut.
Prezzo delle azioni
$15.96
Ultima sincronizzazione: 2025-04-15
Capitalizzazione di mercato
$875.31M
Variazione (1 giorno)
-4.14%
Variazione (1 anno)
-0.19%
Paese
US
Scambia Cara Therapeutics, Inc. (CARA)
Categoria
Healthcare
Capitalizzazione di mercato di Cara Therapeutics, Inc.(CARA)
Capitalizzazione di mercato: $875.31M
A partire dal October 2026, Cara Therapeutics, Inc. ha una capitalizzazione di mercato pari a $875.31M. Questo rende Cara Therapeutics, Inc. la 9894th azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di Cara Therapeutics, Inc. dal 2018 al 2026
CARA in paragone con la classifica dei più popolari stocks
| Il prezzo per CARA | Attivo B | Capitalizzazione del mercato a B | Risultati | |
|---|---|---|---|---|
$3,395,620
$24.33M
|
$5.167T | +21,235,796.41% | ||
|
$3,295,559
$24.33M
|
$5.015T | +20,610,023.16% | ||
|
$2,699,916
$24.33M
|
$4.108T | +16,884,925.87% | ||
|
$2,564,211
$24.33M
|
$3.902T | +16,036,242.67% | ||
|
$1,767,428
$24.33M
|
$2.689T | +11,053,232.26% |
